{
    "symbol": "FGEN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-09 23:25:21",
    "content": "  FibroGen is positioned to create significant value for patients and shareholders by executing on our three areas of focus: number one, accelerating the development of pamrevlumab in three indications with significant unmet medical needs, idiopathic pulmonary fibrosis, or IPF, locally advanced unresectable pancreatic cancer, or LAPC, and Duchenne muscular dystrophy, or DMD; number two, ensuring commercial success of roxadustat in patients with chronic kidney disease outside the U.S., while continue to explore a path forward in the U.S.; and number three, increasing our research productivity to advance novel programs that leverage internal expertise and accessing external innovation for additional pipeline opportunities."
}